chugai pharmaceutical co ltd
(4519:Tokyo)
As of 12:09 AM 05/20/13 All times are local (Market data is delayed by at least 15 minutes).
Financial Statements for chugai pharmaceutical co ltd (4519)
Year over year, Chugai Pharmaceutical Co. Ltd. has been able to grow revenues from ¥363.6B JPY to ¥391.2B JPY. Most impressively, the company has been able to reduce the percentage of sales devoted to selling, general and administrative costs from 26.87% to 23.51%. This was a driver that led to a bottom line growth from ¥35.2B JPY to ¥48.2B JPY.
View Income Statement In U.S. Dollar| Currency in Millions of Japanese Yens | As of: | Dec 31 2009 Restated JPY | Dec 31 2010 JPY | Dec 31 2011 JPY | Dec 31 2012 JPY | 4 Year Trend |
| Revenues | 419,106.0 | 375,560.0 | 363,622.0 | 391,220.0 |  | |
| TOTAL REVENUES | 428,947.0 | 379,510.0 | 373,517.0 | 391,220.0 | | |
| Cost of Goods Sold | 192,851.0 | 162,418.0 | 157,507.0 | 167,726.0 | | |
| GROSS PROFIT | 236,096.0 | 217,092.0 | 216,010.0 | 223,494.0 | | |
| Selling General & Admin Expenses, Total | 98,168.0 | 96,151.0 | 97,723.0 | 91,973.0 | | |
| R&D Expenses | 55,315.0 | 54,703.0 | 55,857.0 | 55,107.0 | | |
| OTHER OPERATING EXPENSES, TOTAL | 153,483.0 | 150,854.0 | 153,580.0 | 147,080.0 | | |
| OPERATING INCOME | 82,613.0 | 66,238.0 | 62,430.0 | 76,414.0 | | |
| Interest Expense | -20.0 | -4.0 | -4.0 | -4.0 | | |
| Interest and Investment Income | 753.0 | 450.0 | 842.0 | 478.0 | | |
| Other Non-Operating Expenses, Total | 7,287.0 | -1,336.0 | -316.0 | -2,464.0 | | |
| Other Non-Operating Income (Expenses) | 986.0 | 549.0 | -848.0 | 732.0 | | |
| Merger & Restructuring Charges | -1,228.0 | 480.0 | -69.0 | -- | | |
| Gain (Loss) on Sale of Investments | -13.0 | 91.0 | -217.0 | -4.0 | | |
| Gain (Loss) on Sale of Assets | 51.0 | -192.0 | -667.0 | -354.0 | | |
| Other Unusual Items, Total | -27.0 | -41.0 | -4,868.0 | 1,255.0 | | |
| EBT, INCLUDING UNUSUAL ITEMS | 89,416.0 | 65,686.0 | 57,131.0 | 75,321.0 | | |
| Income Tax Expense | 31,183.0 | 23,096.0 | 20,856.0 | 26,330.0 | | |
| Minority Interest in Earnings | -1,599.0 | -1,157.0 | -1,040.0 | -786.0 | | |
| Earnings from Continuing Operations | 58,233.0 | 42,590.0 | 36,275.0 | 48,991.0 | | |
| NET INCOME | 56,634.0 | 41,433.0 | 35,235.0 | 48,205.0 | | |
| NET INCOME TO COMMON INCLUDING EXTRA ITEMS | 56,634.0 | 41,433.0 | 35,235.0 | 48,205.0 | | |
| NET INCOME TO COMMON EXCLUDING EXTRA ITEMS | 56,634.0 | 41,433.0 | 35,235.0 | 48,205.0 | | |
| Recently Viewed | |||
| 4519:JP | ¥2,434.00 JPY | -8.00 |  |
| Company | Last | Change |
| Amgen Inc | $105.63 USD | +0.66 |
| Celgene Corp | $124.91 USD | +1.43 |
| Eisai Co Ltd | ¥4,460 JPY | -35.00 |
| Emergent Biosolutions Inc | $14.56 USD | +0.13 |
| Hospira Inc | $35.74 USD | +0.02 |
| View Industry Companies | ||
Industry Analysis
4519
Industry Average
| Valuation | 4519 | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: Apr 29
